Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 5, 2011, Pages 1395-1401

  Brade, Anthony ^a   Bezjak, Andrea ^a   MacRae, Robert ^c   Laurie, Scott ^c   Sun, Alex ^a   Cho, John ^a   Leighl, Natasha ^b   Pearson, Shannon ^a   Southwood, Bernadette ^b   Wang, Lisa ^b   McGill, Shauna ^b   Iscoe, Neill ^d,e   Shepherd, Frances A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d ELI LILLY AND COMPANY   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Chemoradiotherapy; Non small cell lung cancer; Pemetrexed; Phase I trial; Radiotherapy

Indexed keywords

ACUTE ESOPHAGITIS; CHEMORADIOTHERAPY; CIS-PLATIN; CYTOTOXIC AGENTS; DOSE LEVELS; DOSE LIMITING TOXICITY; HEMATOLOGIC TOXICITY; MEDIAN RADIATION; NON-SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PEMETREXED; PERFORMANCE STATUS; PHASE I; PHASE I TRIAL; PHASE II; RESPONSE RATE; THIRD GENERATION; WEIGHT LOSS;

BIOLOGICAL ORGANS; DISEASES; DOSIMETRY; PLATINUM COMPOUNDS; TOXICITY;

RADIOTHERAPY;

CISPLATIN; CYANOCOBALAMIN; FOLIC ACID; PEMETREXED;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS STRICTURE; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ODYNOPHAGIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY;

EID: 79952705623     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.01.014     Document Type: Article

References (30)

1. Garcia M, Jemal A, Ward EM, et al. Global cancer facts & figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-462.
3. Auperin A, Rolland E, Curran WJ, et al. Concomitant radiochemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC) - a meta-analysis using individual patient data from randomised clinical trials (Abstr). J Thorac Oncol 2007;2:S310.
4. NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
5. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5760.
6. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III sudy of gemcitabine-cisplatin versus etoposidecisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999;17:12-18. (Pubitemid 29022372)
7. Chen Y, Okunieff P. Radiation and third-generation chemotherapy. Hematol Oncol Clin North Am 2004;18:55-80. (Pubitemid 38201549)
8. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
9. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-smallcell lung cancer. J Clin Oncol 2008;26:3543-3551.
10. Vrouchou P, Kandaswamy P, George E, et al. Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: Summary of the NICE appraisal. Lancet Oncol 2009;10:1031-1032.
11. Bischof M, Weber KJ, Blatter J, et al. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 2002;52:1381-1388. (Pubitemid 34302884)
12. Teicher BA, Alvarez E, Liu P, et al. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 1999;26:55-62. (Pubitemid 29218029)
13. Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007;13:515-522. (Pubitemid 46225357)
14. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-3024. (Pubitemid 46606280)
15. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859. (Pubitemid 41079865)
16. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002;13:1539-1549. (Pubitemid 35331451)
17. Zojwalla NJ,RaftopoulosH,Gralla RJ.Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive reviewof randomized studies in over 2300 patients (Abst.). J Clin Oncol 2004;22:7068.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
19. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-552.
20. Greco FA, Stroup SL, Gray JR, et al. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 1996;14:1642-1648. (Pubitemid 26134223)
21. Mudad R, Ramsey M, Kovitz K, et al. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced nonsmall cell lung cancer: A dose finding study. Lung Cancer 2003;39:173-177. (Pubitemid 36173618)
22. Robert F, Spencer SA, Childs HA 3rd, et al. Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: Long-term follow-up of a phase I trial. Lung Cancer 2002;37:189-199. (Pubitemid 34835688)
23. Vokes EE, Herndon JE 2nd, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 2002;20:4191-4198. (Pubitemid 35191021)
24. Wu HG, Bang YJ, Choi EK, et al. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:75-80. (Pubitemid 34044107)
25. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-165.
26. Chen Y, Pandya KJ, Feins R, et al. Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;71:407-413.
27. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
28. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. Oncologist 2009;14:253-263.
29. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
30. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596. (Pubitemid 44546920)